Neelima Vidula

1.3k total citations
67 papers, 719 citations indexed

About

Neelima Vidula is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Neelima Vidula has authored 67 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Neelima Vidula's work include Advanced Breast Cancer Therapies (26 papers), Cancer Genomics and Diagnostics (15 papers) and BRCA gene mutations in cancer (14 papers). Neelima Vidula is often cited by papers focused on Advanced Breast Cancer Therapies (26 papers), Cancer Genomics and Diagnostics (15 papers) and BRCA gene mutations in cancer (14 papers). Neelima Vidula collaborates with scholars based in United States, Israel and Spain. Neelima Vidula's co-authors include Hope S. Rugo, Aditya Bardia, Leif W. Ellisen, Christina Yau, Aiko Nagayama, X. Cynthia, Beverly Moy, Steven J. Isakoff, Laura M. Spring and Seth A. Wander and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Neelima Vidula

60 papers receiving 711 citations

Peers

Neelima Vidula

ONCOL

PRM

RNMI

Reshma Mahtani United States

Olga Martínez‐Sáez Spain

Erica Stringer-Reasor United States

Parvin F. Peddi United States

Eduardo Martínez de Dueñas Spain

Pietro De Placido Italy

Daniele Andreis Italy

Rossella Martinello Italy

Andrea Milani Italy

Reshma Mahtani United States

Neelima Vidula

438 ×0.9

ONCOL

229 ×0.7

PRM

194 ×1.0

142 ×0.8

110 ×1.2

RNMI

Citations per year, relative to Neelima Vidula Neelima Vidula (= 1×) peers Reshma Mahtani

Countries citing papers authored by Neelima Vidula

Since Specialization

Citations

This map shows the geographic impact of Neelima Vidula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neelima Vidula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neelima Vidula more than expected).

Fields of papers citing papers by Neelima Vidula

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neelima Vidula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neelima Vidula. The network helps show where Neelima Vidula may publish in the future.

Co-authorship network of co-authors of Neelima Vidula

This figure shows the co-authorship network connecting the top 25 collaborators of Neelima Vidula. A scholar is included among the top collaborators of Neelima Vidula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neelima Vidula. Neelima Vidula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sood, Rupali, Andrzej Niemierko, Laura M. Spring, et al.. (2025). Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer. Clinical Cancer Research. 31(7). 1315–1322. 1 indexed citations

Bar, Yael, Andrzej Niemierko, Arielle J. Medford, et al.. (2024). Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. npj Breast Cancer. 10(1). 27–27. 2 indexed citations

Vidula, Neelima, Senthil Damodaran, Manali Bhave, et al.. (2024). Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping. Cancer Research. 84(9_Supplement). PO4–19. 1 indexed citations

Sherazi, Saadia, Scott McNitt, Carla Casulo, et al.. (2023). Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association. 12(6). e025786–e025786. 1 indexed citations

Medford, Arielle J., Ignaty Leshchiner, Lesli A. Kiedrowski, et al.. (2023). ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1074–1074. 1 indexed citations

Chen, Nan, Rita Nanda, Frederick M. Howard, et al.. (2023). Abstract P5-03-18: Co-occurring alterations in PALB2 germline carriers identified by liquid biopsy in patients with advanced breast cancer. Cancer Research. 83(5_Supplement). P5–3.

Vidula, Neelima, Senthil Damodaran, Manali Bhave, et al.. (2023). Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).. Journal of Clinical Oncology. 41(16_suppl). TPS1134–TPS1134. 2 indexed citations

Vidula, Neelima, Andrzej Niemierko, Beverly Moy, et al.. (2023). Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. npj Breast Cancer. 9(1). 29–29. 4 indexed citations

Vidula, Neelima, Christina Yau, & Hope S. Rugo. (2022). Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Research and Treatment. 194(3). 569–575. 37 indexed citations

10.

Vidula, Neelima, Shumei Kato, Caroline Weipert, et al.. (2022). Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. npj Breast Cancer. 8(1). 117–117. 8 indexed citations

11.

Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413. 12 indexed citations

12.

Nagayama, Aiko, Neelima Vidula, & Aditya Bardia. (2021). Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. PubMed. 35(3505). 249–254. 21 indexed citations

13.

Vidula, Neelima, Sally Greenberg, Laura F. Petrillo, et al.. (2021). Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. npj Breast Cancer. 7(1). 113–113. 16 indexed citations

14.

Vidula, Neelima, Christina Yau, & Hope S. Rugo. (2021). Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Research and Treatment. 187(2). 387–395. 11 indexed citations

15.

Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262. 15 indexed citations

16.

Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451. 47 indexed citations

17.

Vidula, Neelima, Christina Yau, Denise M. Wolf, & Hope S. Rugo. (2019). Androgen receptor gene expression in primary breast cancer. npj Breast Cancer. 5(1). 47–47. 29 indexed citations

18.

Rugo, Hope S., Neelima Vidula, & X. Cynthia. (2016). Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. American Society of Clinical Oncology Educational Book. 35(36). e40–e54. 37 indexed citations

19.

Vidula, Neelima, Irene Helenowski, Borko Jovanovic, et al.. (2015). Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. Clinical Lymphoma Myeloma & Leukemia. 15(11). e157–e162. 12 indexed citations

20.

Vidula, Neelima, et al.. (2006). Ultrasound Accelerated Bone Tissue Engineering Monitored with Magnetic Resonance Microscopy. PubMed. 2006. 484–488. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact